Thoratec Corp THOR recently announced that the HeartMate III CE mark trial has successfully met its primary endpoint. HeartMate III is a next-generation continuous-flow left ventricular assist device ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

FDA has granted Thoratec Corp. permission to enlarge its pivotal trial for the next-generation HeartMate III left ventricular assist system (LVAS). This gives the company the ability to enroll a ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

Manufacturer and marketer of medical devices used for mechanical circulatory support, Thoratec Corp.THOR, recently announced that the first HeartMate III implant has been conducted via ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final ...

The success rate was "quite high" and the survival "quite good" with the new device, which showed noninferiority when compared with patients in a national registry, most of whom had gotten the ...

In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.